Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
or

Akari Therapeutics ADR (AKTX)

Akari Therapeutics ADR (AKTX)
0.8670 x 6 1.5500 x 8
Post-market by (Cboe BZX)
1.2050 +0.1050 (+9.55%) 04/17/25 [NASDAQ]
0.8670 x 6 1.5500 x 8
Post-market 1.2050 unch (unch) 14:37 ET
Quote Overview for Thu, Apr 17th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
1.1000
Day High
1.2799
Open 1.1000
Previous Close 1.1000 1.1000
Volume 17,200 17,200
Avg Vol 15,395 15,395
Stochastic %K 53.13% 53.13%
Weighted Alpha -36.71 -36.71
5-Day Change +0.0950 (+8.56%) +0.0950 (+8.56%)
52-Week Range 0.8500 - 4.4000 0.8500 - 4.4000
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 32,045
  • Shares Outstanding, K 26,593
  • Annual Sales, $ 0 K
  • Annual Income, $ -10,010 K
  • EBIT $ -19 M
  • EBITDA $ -19 M
  • 60-Month Beta 0.57
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year 0.00
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0100 +19.31%
on 04/07/25
Period Open: 1.1000
1.7300 -30.35%
on 03/20/25
+0.1050 (+9.55%)
since 03/17/25
3-Month
0.8500 +41.76%
on 03/03/25
Period Open: 1.1890
1.7300 -30.35%
on 03/20/25
+0.0160 (+1.35%)
since 01/17/25
52-Week
0.8500 +41.76%
on 03/03/25
Period Open: 1.1212
4.4000 -72.61%
on 07/26/24
+0.0838 (+7.47%)
since 04/17/24

Most Recent Stories

More News
Akari Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update

AKTX : 1.2050 (+9.55%)
This Micro Cap Continues This Week's Dominance Amid New CEO Appointment

A London-based %Healthcare company found success Thursday after the company announced that it had appointed a new CEO. The new executive is Abizer Gaslightwala, who was most recently senior vice president...

AKTX : 1.2050 (+9.55%)
Akari Therapeutics Appoints Biotechnology Industry Leader, Abizer Gaslightwala, as President and Chief Executive Officer

AKTX : 1.2050 (+9.55%)
Akari Therapeutics Announces $7.6 Million Private Placement Offering Led by Existing Shareholders and Insiders Priced at the Market Under Nasdaq Rules

AKTX : 1.2050 (+9.55%)
Akari Therapeutics Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

AKTX : 1.2050 (+9.55%)
Virtual Investor "Top 5 for '25" Conference Hosted by JTC Now Available On-Demand

- Access video webcasts from the first wave of participating companies here

AKTX : 1.2050 (+9.55%)
AREC : 1.2900 (+16.22%)
OTLK : 1.4500 (+5.84%)
AMIX : 1.8520 (+4.63%)
CNSP : 0.8200 (-0.01%)
PALI : 0.7199 (+2.80%)
NVNO : 2.45 (+2.94%)
HURA : 4.15 (+0.24%)
GRI : 1.5100 (-1.31%)
Akari Therapeutics Joins Webull Corporate Connect Service Platform

AKTX : 1.2050 (+9.55%)
Akari Therapeutics Announces Appointment of Samir R. Patel, M.D. as CEO and Abizer Gaslightwala to Board of Directors

Akari Therapeutics announces Samir R. Patel as CEO and Abizer Gaslightwala's appointment to the Board of Directors.Quiver AI SummaryAkari Therapeutics, Plc announced the appointment of Samir R. Patel,...

AKTX : 1.2050 (+9.55%)
Akari Therapeutics Announces Key Leadership Appointments

AKTX : 1.2050 (+9.55%)
Akari Therapeutics Appoints Torsten Hombeck, Ph.D. as Chief Financial Officer

Akari Therapeutics appoints Dr. Torsten Hombeck as CFO, strengthening leadership with expertise in biotechnology and finance.Quiver AI SummaryAkari Therapeutics, Plc announced the appointment of Dr. Torsten...

AKTX : 1.2050 (+9.55%)

Business Summary

Akari Therapeutics PLC is a biopharmaceutical company. It focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases. The Company's lead drug consist of Coversin is a recombinant small protein, which acts on complement component-C5,...

See More

Key Turning Points

3rd Resistance Point 1.4698
2nd Resistance Point 1.3749
1st Resistance Point 1.2899
Last Price 1.2050
1st Support Level 1.1100
2nd Support Level 1.0151
3rd Support Level 0.9301

See More

52-Week High 4.4000
Fibonacci 61.8% 3.0439
Fibonacci 50% 2.6250
Fibonacci 38.2% 2.2061
Last Price 1.2050
52-Week Low 0.8500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro